Omaveloxolone
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications
Pharmacotherapy of neuromuscular diseases : what's new in 2025
Journal: Revue medicale suisse
Published: January 16, 2026
The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives.
Journal: Journal of natural products
Published: December 26, 2025
Transcriptomic profiling of human endothelial cells infected with venezuelan equine encephalitis virus reveals NRF2 driven host reprogramming mediated by omaveloxolone treatment.
Journal: Frontiers in genetics
Published: October 10, 2025
Nrf2/ARE pathway agonist omaveloxolone attenuates adverse cardiac remodeling in pressure-induced cardiac dysfunction.
Journal: Journal of cardiovascular pharmacology
Published: October 07, 2025
Attenuation of cerebral ischemia-reperfusion induced neurotoxicity by telmisartan, ertugliflozin, and omaveloxolone through Nrf2/HO-1 pathway modulation: In vivo and in silico insights.
Journal: Toxicology reports
Published: October 05, 2025
Synthetic Oleanane Triterpenoids Reduce Tumor Growth and Promote an Anti-Tumor Immune Response Independent of Cancer KEAP1 Mutational Status.
Journal: Antioxidants (Basel, Switzerland)
Published: September 30, 2025
Synthesis and Biological Profile of Omaveloxolone: The Cornerstone for Friedreich Ataxia Treatment.
Journal: International journal of molecular sciences
Published: September 05, 2025
Treatment of primary adult-onset neurodegenerative cerebellar ataxias.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: August 22, 2025
Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA study.
Journal: The Lancet regional health. Europe
Published: August 06, 2025
Oxidative Stress and Antioxidant Therapies in Friedreich's Ataxia.
Journal: Cells
Published: July 31, 2025
Last Updated: 02/24/2026